Paid, then sent elsewhere: a teardown of Maple's intake

Maple's care gets high marks. The frustration that keeps appearing is narrower: a patient pays or uses a visit, and is then told to see someone in person. I think the fix belongs at intake, before the payment screen.

What this is based on

This is an outside view. I have not used Maple as a patient and I have no inside information. I read its website, help centre, app listings, job postings and public reviews on 3 October 2026. I trained as a pharmacist and have redesigned hospital workflows, so triage and handoffs are familiar ground.

The product

Maple offers round-the-clock visits with Canadian doctors and nurse practitioners by text, audio or video. Membership is $85 a month outside Quebec and covers the family. Some provinces fund visits publicly. Maple says eight million Canadians have access through employers, insurers and governments.

The App Store rating is 4.8 from about 46,000 ratings. People praise the speed and not having to sit in a walk-in clinic.

The problem

A BC review of Maple says the consistent complaints are about what practitioners will not do online: controlled substances are not prescribed, some issues need an in-person examination, and a visit can end with advice to go to a clinic anyway. Individual app reviews I read said the same thing with more feeling. My sample was a few dozen reviews, so I will not put a number on it.

The published journey shows why it stings. The patient describes their symptoms, pays, and then enters the waiting room. Maple says each request is reviewed by licensed providers, who can decide it cannot be managed safely online. For the patient, the decision that matters most arrives after the money has moved.

Why it matters

The redirect is often the right clinical call. Chest pain should not be treated by text. The product problem is the order of events, and it costs Maple in three ways.

• Trust. A patient who feels charged for nothing tells other people. Refund rules are a second complaint theme, and the two feed each other.
• Clinician time. Every avoidable redirect is a review that produced no care.
• Strategy. In May 2026 Maple described itself as an essential health-care service that is always available, more than a place to visit when something goes wrong. A patient whose first visit ends in a redirect is unlikely to return for ongoing care.

What Maple already knows

Maple publishes a list of requests it cannot handle: emergencies, anything needing a physical exam, disability and insurance paperwork, driver's medicals, return-to-work forms. It also states that practitioners cannot prescribe controlled substances. So the rules exist. They sit in the help centre, where a worried patient at 2 a.m. will not look.

What I would build first

A suitability check between the symptom step and the payment step.

1. Catch the known cases early. If the request matches the published list, say so before payment: "A Maple provider cannot complete a disability form. Here is who can."
2. Be honest about the grey cases. "Requests like this are sometimes redirected to in-person care. If yours is, you will not be charged." The second sentence is a pricing decision, and I would argue for it.
3. Make the redirect useful. The patient should leave with something: where to go, how urgent it is, and a short summary to hand to the next clinician.
4. Keep clinicians in charge. The check informs the patient. It never blocks a visit. Maple already says triage decisions are made by medical professionals and not by AI, and I would hold that line.

What I would not do

I would not build a model that rejects requests automatically. Turning away someone who needed care is far worse than a refund. I would also not use the check to push memberships. The goal is fewer bad surprises.

How I would measure it

• Share of paid visits that end in a redirect or decline.
• Refund requests and support contacts per 1,000 visits.
• Share of redirected patients who come back within 90 days.
• A safety guardrail: no rise in patients who abandon intake and should have been seen.

What I cannot see

I do not know the real redirect rate, how it differs between members and one-off patients, or how publicly funded visits change the picture. Maple is hiring a product manager for patient access and navigation, so the team may already be working on this. I would want to hear what they have tried.